BY MARLEY WIEMERS

For people who have experienced a heart attack or stroke, taking a daily aspirin has been shown to help prevent a second one. Yet, despite aspirin’s low cost and its clear benefits in such scenarios, fewer than half of people worldwide who have had a heart attack or stroke take the medication, according to a new study led by researchers at Washington University School of Medicine in St. Louis and the University of Michigan. The study appeared Aug. 22 in JAMA (the Journal of the American Medical Association).

Cardiovascular disease, including heart attack and stroke, is the leading cause of death globally. In the 1970s, Washington University’s Philip Majerus, MD, was the first to explain aspirin’s role in blood clotting and the first to propose daily low-dose aspirin as a preventive therapy for cardiovascular disease. Multiple studies in subsequent years established that antiplatelet therapy—including aspirin—can reduce the risk of a second cardiovascular event by about one-quarter. Since then, daily aspirin has been recommended for this purpose. This therapy generally is affordable. In the U.S., a monthly supply of baby aspirin (81 milligrams per dose) can cost from $2 to $8, depending on the retailer and the amount purchased.

Myriad factors contribute to the risk of heart attacks and strokes, including smoking, diabetes, unhealthy diet, genetics, lack of exercise, obesity and even air pollution. Aspirin works as a blood thinner, preventing small blood cells, called platelets, from forming clots. These clots can block arteries and contribute to a reduction in the amount of oxygen-rich blood being delivered to vital organs. Such blockage also can cause, among other conditions, a heart attack or stroke.

“Survivors of heart attacks and stroke often face a high risk of having subsequent events,” says the study’s first author Sang Gune Yoo, MD, a Washington University cardiovascular disease fellow. “In fact, many people die from having recurring attacks. Aspirin offers one effective and relatively low-cost option for reducing the likelihood of additional events in individuals with established cardiovascular disease, and yet most people who could benefit from a daily aspirin don’t take it.”

According to Yoo, the new study can’t explain why aspirin is so underused, but there likely are multiple intersecting explanations, including varying accessibility to health care in general, inconsistent messaging surrounding use of the drug, and the fact that aspirin is not always available over the counter, requiring a prescription in some countries.

The researchers, including senior author David Flood, MD, an assistant professor in the Division of Hospital Medicine at the University of Michigan, analyzed data from nationally representative health surveys that were conducted in 51 low-, middle- and high-income countries. The surveys included questions about people’s medical history of cardiovascular disease and on aspirin use. The study included 125,505 individuals, with 10,590 self-reporting a history of cardiovascular disease.

Despite the benefits of aspirin, the study showed that in low-income countries, only 16.6% of eligible individuals—those who had experienced a first heart attack or stroke—were taking aspirin to prevent a second heart attack or stroke. In lower-middle-income countries this number was 24.5%. It increased to 51.1% for upper-middle-income countries, and to 65% in high-income countries, including the United States.

An earlier study that was conducted by a different group of researchers, the Prospective Urban Rural Epidemiology cohort study, was published in 2011 and found similarly low aspirin usage. Despite international efforts to improve access to cardiovascular disease medicines, including aspirin, from 2011 through 2023, aspirin remains severely underused. Yoo says this lack of progress underscores the urgent need to continue developing and implementing interventions to promote aspirin use.

Interventions, according to Yoo, should take a multipronged approach and should consider the contexts in which they’re being implemented. Such approaches could involve repurposing system-level strategies deployed to manage other chronic conditions, such as HIV/AIDS. “Particularly in lower-middle-income countries, there is often a good infrastructure for caring for patients living with HIV or other endemic disease,” Yoo notes. “We can think about restructuring that so that we can also address comorbidities of heart attack and stroke, such as cardiovascular disease, as part of those existing systems, instead of having to reinvent the wheel.”

Interventions also could take place where aspirin is easily available, targeting pharmacies or primary care physicians to make the drug more accessible to eligible patients. “In order to create interventions, we have to understand what is actually going on, which is what we’re trying to establish in this study,” Yoo says. “Then we can start to think about how to develop strategies to increase evidence-based aspirin use in order to save lives.”

Originally published by Washington University School of Medicine.